Acorda appoints Jane Wasman international president
This article was originally published in Scrip
Acorda Therapeutics, a biotech company focused on neurological conditions, has named Jane Wasman international president. Ms Wasman most recently served as Acorda's chief of strategic development and general counsel.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.